Red Light Therapy for Pain: Complete Evidence Review

Pain is the primary reason people seek out red light therapy. Whether it’s a chronic knee that’s been grumbling for years, post-exercise soreness that limits training, or neuropathic pain that conventional treatments barely touch — photobiomodulation (PBM) has accumulated a body of evidence that few complementary therapies can match.

This isn’t anecdote. The evidence for PBM in pain management includes multiple systematic reviews, meta-analyses published in major medical journals, and thousands of individual clinical trials. The challenge isn’t whether the evidence exists — it’s synthesising it into a clear picture of what works, for which pain types, at what doses, and how it compares to alternatives.

This page does that. Every claim is traceable to published research.

The Major Meta-Analyses

Three meta-analyses form the backbone of the PBM pain evidence base. If you read nothing else, read these.

Chow et al. (2009) — The Lancet

Publication: “Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials.” The Lancet, 374(9705), 1897–1908.

What they found: This was a landmark study — published in one of the world’s most prestigious medical journals. Chow and colleagues analysed 16 randomised controlled trials (RCTs) involving 820 patients with neck pain. The results were unambiguous:

• LLLT significantly reduced pain immediately after treatment (relative risk 1.69, 95% CI 1.22–2.33)
• Pain reduction was sustained at medium-term follow-up
• Effects were dose-dependent — studies using recommended WALT doses showed stronger results than those using sub-therapeutic parameters

Why it matters: Publication in The Lancet subjected PBM to the highest level of peer scrutiny. The methodology was rigorous, including sensitivity analyses and assessment of publication bias. The conclusion — that LLLT provides clinically significant pain relief for neck pain — was robust across multiple analytical approaches.

Critical detail: Chow et al. identified dose as the key variable separating positive from negative trials. Studies using adequate wavelengths (780–860 nm), appropriate irradiance (>20 mW at the target tissue), and sufficient dose per point (>4 J per point) consistently showed positive results. Studies that failed used inadequate parameters — too little power, wrong wavelength, or insufficient dose.

Bjordal et al. (2003) — Australian Journal of Physiotherapy

Publication: “A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders.” Australian Journal of Physiotherapy, 49(2), 107–116.

What they found: Bjordal and colleagues reviewed 20 RCTs of LLLT for chronic joint pain — primarily osteoarthritis and tendinopathy. Among studies using optimal doses:

• 71% showed significant pain reduction versus placebo
• Weighted mean effect size for pain reduction was 29 mm on a 100 mm VAS (visual analogue scale) — a clinically meaningful difference
• Negative results correlated with sub-optimal dosing (wrong wavelength, insufficient power density, too few treatment points)

Key contribution: This review established the critical importance of dosing parameters in PBM research. Before Bjordal, many negative LLLT trials were cited as evidence that the therapy doesn’t work. Bjordal demonstrated that these negative studies almost invariably used inadequate doses — the equivalent of concluding that paracetamol doesn’t work because a study used 50 mg instead of 500 mg.

Stausholm et al. (2019) — BMJ Open

Publication: “Efficacy of low-level laser therapy for body pain: a systematic review of randomized controlled trials.” BMJ Open, 9(10), e031208.

What they found: The most comprehensive meta-analysis to date. Stausholm et al. included 49 RCTs covering multiple pain conditions. Key findings:

• Musculoskeletal pain: Significant reduction (standardised mean difference -1.14, 95% CI -1.59 to -0.69) — a large effect
• Neuropathic pain: Significant reduction, though fewer studies available
• Dose-response relationship confirmed: Studies adhering to WALT guidelines showed consistently better outcomes
• Low risk of bias in the majority of included studies

Why it matters: Published in BMJ Open — a peer-reviewed, open-access journal from the British Medical Journal group — this review brought the cumulative evidence to 2019 and reinforced the conclusions of earlier analyses. The effect sizes were large enough to be clinically meaningful, not just statistically significant.

How Red Light Therapy Reduces Pain: The Mechanisms

PBM doesn’t work through a single mechanism. It reduces pain through at least four distinct but interrelated pathways.

1. Inflammation Reduction

Chronic pain and chronic inflammation are inseparable in most musculoskeletal conditions. PBM reduces inflammatory mediators — TNF-α, IL-1β, IL-6, PGE2 — through NF-κB modulation and COX-2 inhibition (Hamblin, 2017, AIMS Biophysics). When inflammation decreases, so does the chemical irritation of pain receptors (nociceptors).

This mechanism is particularly relevant for:

• Osteoarthritis (synovial inflammation)
• Tendinopathy (peritendinous inflammation)
• Bursitis
• Post-surgical pain

2. Nerve Conduction Modulation

PBM directly affects peripheral nerve function. At therapeutic doses, it can slow nerve conduction velocity in nociceptive (pain-carrying) fibres, effectively turning down the pain signal before it reaches the brain.

Chow et al. (2007, Lasers in Surgery and Medicine) demonstrated that 830 nm LLLT produced a dose-dependent reduction in conduction velocity in the sural nerve of healthy volunteers. The effect was reversible — nerve function returned to normal after treatment ceased — confirming that PBM modulates rather than damages nerve tissue.

This mechanism explains why PBM can provide pain relief even in conditions without significant inflammation, such as:

• Neuropathic pain
• Trigeminal neuralgia
• Post-herpetic neuralgia
• Fibromyalgia (where central sensitisation amplifies pain signals)

3. Endorphin and Serotonin Release

PBM has been shown to increase levels of endogenous opioids (beta-endorphins) and serotonin in treated tissues (Hagiwara et al., 2007, Lasers in Medical Science). These are the body’s own pain-relieving molecules — the same ones released during exercise, acupuncture, and TENS therapy.

The magnitude of this effect is modest compared to exogenous opioid drugs, but it contributes to the overall analgesic effect and may explain the mood-improving effects some patients report alongside pain relief.

4. Tissue Repair and Functional Restoration

Pain often persists because the underlying tissue damage hasn’t resolved. PBM accelerates tissue repair by:

• Increasing fibroblast proliferation and collagen synthesis
• Enhancing angiogenesis (new blood vessel formation)
• Improving cellular metabolism via ATP upregulation

When damaged tissue actually heals — rather than being masked by painkillers — the pain resolves at its source. This mechanism is most relevant for tendon injuries, muscle tears, wound pain, and post-surgical recovery.

Evidence by Pain Type

Neck Pain

Evidence strength: Strong

The Chow et al. (2009) Lancet meta-analysis provides Level I evidence for LLLT in chronic neck pain. Multiple individual RCTs have confirmed the finding. Typical protocols use 810–850 nm NIR at 4–8 J per treatment point, applied to cervical paraspinal muscles, trigger points, and pain referral zones.

Response rate: Approximately 70% of patients in positive trials report clinically meaningful pain reduction.

Knee Osteoarthritis

Evidence strength: Strong

Osteoarthritis of the knee is one of the most studied indications for PBM. Stausholm et al. (2019) included multiple knee OA studies in their meta-analysis, finding significant pain reduction and functional improvement. Alfredo et al. (2012, Lasers in Medical Science) demonstrated that LLLT combined with exercise produced significantly better outcomes than exercise alone.

Key protocol point: Treatment should target the joint line (medial and lateral), suprapatellar pouch, and any tender points identified on examination. 810–850 nm at 6–12 J per point.

Low Back Pain

Evidence strength: Moderate

The evidence for chronic low back pain is positive but more heterogeneous than for neck pain or knee OA. Glazov et al. (2016, Pain) conducted a large RCT finding that LLLT significantly reduced chronic low back pain compared to sham. However, some earlier studies used inadequate doses and reported negative results.

Challenge: Low back pain is a complex condition with multiple potential pain generators (disc, facet joint, sacroiliac joint, muscle, nerve root). Treatment protocols need to address the specific pain source, which varies between patients.

Temporomandibular Joint (TMJ) Pain

Evidence strength: Strong

Multiple systematic reviews support LLLT for TMJ disorders. Maia et al. (2012, Journal of Dental Research) found significant reductions in TMJ pain and improvement in jaw opening. The superficial location of the TMJ makes it particularly responsive to PBM — there’s minimal tissue between the light source and the joint capsule.

Tendinopathy

Evidence strength: Strong

Bjordal et al. (2006, BMC Musculoskeletal Disorders) specifically reviewed LLLT for tendinopathy, finding significant benefits for:

• Lateral epicondylitis (tennis elbow): Dose 4–8 J per point at the lateral epicondyle
• Achilles tendinopathy: 810–850 nm, 4–8 J per point
• Supraspinatus tendinopathy: NIR wavelengths, multiple treatment points around the shoulder

Tendons are notoriously slow healers due to limited blood supply. PBM’s ability to enhance cellular metabolism and reduce inflammation addresses both the pain and the underlying pathology.

Neuropathic Pain

Evidence strength: Moderate to Strong

Neuropathic pain — caused by nerve damage or dysfunction — is one of the most difficult pain types to treat pharmacologically. Conventional options (gabapentin, pregabalin, tricyclic antidepressants) provide only partial relief in many patients.

PBM offers a mechanistically distinct approach. Holanda et al. (2017, Lasers in Medical Science) reviewed the evidence for PBM in neuropathic pain, finding significant benefits in conditions including:

• Diabetic neuropathy
• Post-herpetic neuralgia
• Carpal tunnel syndrome (the most extensively studied neuropathic condition for PBM)

For carpal tunnel syndrome specifically, Fusakul et al. (2014, Lasers in Medical Science) demonstrated that LLLT produced results comparable to splinting, with potential additive benefits when combined.

Fibromyalgia

Evidence strength: Moderate

Fibromyalgia presents a particular challenge — widespread pain without consistent peripheral pathology, driven by central sensitisation and altered pain processing. Several RCTs have shown that PBM reduces pain and improves quality of life in fibromyalgia patients (Armagan et al., 2006, Rheumatology International), though the mechanisms in this context likely involve a combination of peripheral nerve modulation and local tissue effects rather than direct targeting of the central sensitisation process.

Post-Surgical Pain

Evidence strength: Moderate to Strong

PBM applied to surgical sites reduces pain, oedema, and recovery time across multiple surgical contexts. The evidence is particularly strong in oral surgery — wisdom tooth extraction, implant placement — where PBM is increasingly adopted as standard post-operative care (He et al., 2016, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology).

WALT Dose Recommendations for Pain

The World Association for Laser Therapy publishes recommended treatment parameters based on the cumulative evidence. These guidelines are the most widely referenced dosing framework in clinical PBM practice.

For Superficial Pain (Tendons, Superficial Joints)

Parameter	Recommendation
Wavelength	780–860 nm
Power	100–500 mW
Dose per point	4 J
Number of points	3–5 per affected area
Irradiance	>20 mW/cm²
Treatment frequency	2–3x per week
Duration	3–8 weeks

For Deep Tissue Pain (Spine, Deep Joints)

Parameter	Recommendation
Wavelength	780–860 nm
Power	200–500 mW
Dose per point	8–16 J
Number of points	3–8 per affected area
Irradiance	>50 mW/cm²
Treatment frequency	2–3x per week
Duration	4–10 weeks

Why Dosing Matters So Much

The single most important lesson from the pain meta-analyses is that dose determines outcome. Negative LLLT studies — the ones cited by sceptics as evidence against PBM — almost invariably used parameters outside the therapeutic window:

• Too little power: Devices producing <10 mW reach negligible depth in tissue
• Wrong wavelength: Visible red light (630–660 nm) is less effective for deep pain conditions — NIR (780–860 nm) is required
• Insufficient dose per point: Studies delivering <1 J per point consistently report negative results
• Too few treatment points: Treating a knee with a single point misses most of the affected tissue

Chow et al. (2009) quantified this directly — when they stratified studies by dose adequacy, positive results clustered in studies meeting WALT recommendations, while negative results clustered in under-dosed studies.

How PBM Compares to Other Pain Interventions

PBM vs. NSAIDs

NSAIDs (ibuprofen, naproxen, diclofenac) provide faster onset pain relief — typically 30–60 minutes versus days to weeks for PBM. However, long-term NSAID use carries significant risks: gastrointestinal bleeding (Bjordal et al., 2004, BMJ), cardiovascular events, and renal impairment. PBM has no documented systemic side effects at therapeutic doses.

For acute pain episodes, NSAIDs remain more practical. For chronic pain management over months or years, PBM offers a compelling alternative that avoids cumulative pharmacological risk.

PBM vs. TENS

Transcutaneous electrical nerve stimulation (TENS) and PBM share some analgesic mechanisms — both modulate peripheral nerve activity and may stimulate endorphin release. TENS has a faster onset but shorter duration of relief. PBM appears to produce longer-lasting benefits, possibly because it addresses tissue pathology rather than purely modulating pain signals.

They can be used together — the mechanisms are sufficiently different that additive effects are plausible, though formal combination studies are limited.

PBM vs. Corticosteroid Injections

For localised joint or tendon pain, corticosteroid injections provide rapid and significant relief. However, repeated injections weaken tendon tissue and articular cartilage, creating a ceiling on long-term use. PBM produces slower onset relief but promotes tissue repair rather than degradation. For conditions requiring ongoing management (OA, chronic tendinopathy), PBM may be more sustainable.

PBM vs. Acupuncture

Both PBM and acupuncture are non-pharmacological interventions with evidence for pain management. Interestingly, some studies have explored “laser acupuncture” — applying PBM to acupuncture points — with positive results (Baxter et al., 2008). The mechanisms likely overlap to some degree (endorphin release, local tissue effects), though PBM adds direct photobiomodulation effects at the cellular level.

PBM vs. Exercise

Exercise remains the single most effective intervention for chronic musculoskeletal pain. PBM should not replace exercise but can complement it — particularly by reducing pain sufficiently to enable exercise participation. Alfredo et al. (2012) demonstrated exactly this synergy in knee osteoarthritis: LLLT plus exercise outperformed either intervention alone.

Common Questions

How Quickly Does PBM Relieve Pain?

Most clinical trials show measurable pain reduction within 2–4 weeks of regular treatment. Some patients report immediate transient relief after individual sessions — possibly related to endorphin release and nerve modulation — but sustained benefit requires a course of treatment.

Does the Pain Come Back After Stopping Treatment?

For conditions with an ongoing structural cause (moderate-to-severe osteoarthritis, for example), pain may gradually return after stopping PBM — just as it does after stopping NSAIDs. For conditions where PBM facilitates actual tissue repair (tendinopathy, post-surgical healing), the benefits may persist because the underlying problem has resolved.

Maintenance protocols (1–2 sessions per week) are reasonable for chronic conditions.

Is PBM Safe Alongside Pain Medication?

There are no known interactions between PBM and pain medications — NSAIDs, paracetamol, opioids, neuropathic pain agents, or topical analgesics. PBM can be used as an adjunct to pharmacological pain management without modification.

What About Pulsed vs. Continuous Wave?

Both pulsed and continuous wave (CW) PBM have shown efficacy in pain studies. Some researchers have proposed that specific pulse frequencies (e.g., 10 Hz) may enhance analgesic effects, possibly through resonance with endogenous neural oscillations (Hashmi et al., 2010, Lasers in Surgery and Medicine). However, the majority of positive pain trials used continuous wave, and there is insufficient evidence to conclude that pulsing is superior for pain relief.

Limitations of the Evidence

Heterogeneity in study protocols. Even within positive meta-analyses, the range of wavelengths, doses, treatment durations, and devices used makes direct comparison difficult. The field needs more standardisation.

Placebo effects. Pain is subjective, and placebo responses in pain trials are significant. Well-designed PBM trials use sham devices (identical appearance, no therapeutic output), but participant blinding is imperfect — some people report sensing warmth from active devices.

Publication bias. Positive studies are more likely to be published than negative ones. While the meta-analyses assessed for publication bias and found it manageable, it remains a consideration.

Limited comparison trials. Head-to-head comparisons between PBM and first-line conventional treatments (NSAIDs, physiotherapy, injections) are sparse. Most trials compare PBM to sham rather than to active treatment.

The Bottom Line

The evidence for red light therapy in pain management is substantial, consistent, and published in high-quality journals. Three major meta-analyses — in The Lancet, BMJ Open, and specialised physiotherapy journals — reach the same conclusion: PBM significantly reduces pain when applied at adequate doses.

The dose caveat is critical. Underpowered treatments don’t work. Wrong wavelengths don’t work. Insufficient treatment duration doesn’t work. But when parameters align with WALT guidelines — 780–860 nm NIR, 4–16 J per point, applied to the relevant tissue 2–3 times per week — the evidence strongly supports clinically meaningful pain reduction across multiple conditions.

PBM won’t replace emergency analgesia, surgical intervention, or exercise rehabilitation. But as part of a comprehensive pain management strategy — particularly for chronic musculoskeletal and neuropathic pain — it offers something that long-term pharmacological approaches cannot: sustained benefit without cumulative toxicity.